Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.

Literature DB >> 28075429

Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.

W Zhou^1,2, S Dai^1,2, H Zhu^1,2, Z Song^1,2, Y Cai³, J B Lee³, Z Li³, X Hu², B Fang⁴, C He^1,2, X Huang¹.

Abstract

Peritoneal dissemination is the most common condition of metastasis in gastric cancer. The survival duration of a patient with advanced stage gastric cancer, may be improved by gene therapy. In this study, we used an oncolytic adenovirus vector (Ad/TRAIL-E1) that expresses both the TRAIL and E1A genes under the control of a tumor-specific promoter. We evaluated the anti-tumor effect of Ad/TRAIL-E1 on gastric cancer cells in vitro, as well as in vivo in a xenograft peritoneal carcinomatosis mouse model. Our data showed that Ad/TRAIL-E1 induced TRAIL-mediated apoptosis in gastric cancer cell lines, but not in the normal cell lines. In addition, Ad/TRAIL-E1 significantly inhibited peritoneal metastasis and prolonged the survival of mice without treatment-related toxicity. Therefore, tumor-specific TRAIL expression from an oncolytic adenovirus vector may provide a novel therapeutic approach for the treatment of advance stage gastric cancer with peritoneal dissemination.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28075429 DOI： 10.1038/gt.2017.2

Source DB: PubMed Journal: Gene Ther ISSN： 0969-7128 Impact factor: 5.250

35 in total

1. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.

Authors: Ryo Sakai; Shunsuke Kagawa; Yasumoto Yamasaki; Toru Kojima; Futoshi Uno; Yuuri Hashimoto; Yuichi Watanabe; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara
Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261

Review 2. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale.

Authors: F Roviello; S Caruso; A Neri; D Marrelli
Journal: Eur J Surg Oncol Date: 2013-10-23 Impact factor: 4.424

3. Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis.

Authors: E Querido; J G Teodoro; P E Branton
Journal: J Virol Date: 1997-05 Impact factor: 5.103

4. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer.

Authors: Can Xu; Yunliang Sun; Yunfeng Wang; Yan Yan; Zhengjie Shi; Lei Chen; Han Lin; Shunli Lü; Maoling Zhu; Changqing Su; Zhaoshen Li
Journal: Cancer Lett Date: 2012-01-17 Impact factor: 8.679

5. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors.

Authors: Toshihiro Tanaka; Jianhua Huang; Sachie Hirai; Motomu Kuroki; Masahide Kuroki; Naoki Watanabe; Kei Tomihara; Kazunori Kato; Hirofumi Hamada
Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531

6. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.

Authors: Fengqin Dong; Li Wang; John J Davis; Wenxian Hu; Lidong Zhang; Wei Guo; Fuminori Teraishi; Lin Ji; Bingliang Fang
Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531

7. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors: R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal: J Biol Chem Date: 1996-05-31 Impact factor: 5.157

Review 8. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.

Authors: Florian Kreppel; Stefan Kochanek
Journal: Mol Ther Date: 2007-10-02 Impact factor: 11.454

9. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.

Authors: Michihiro Ishida; Shunsuke Kagawa; Kyoko Shimoyama; Kiyoto Takehara; Kazuhiro Noma; Shunsuke Tanabe; Yasuhiro Shirakawa; Hiroshi Tazawa; Hisataka Kobayashi; Toshiyoshi Fujiwara
Journal: Mol Cancer Ther Date: 2016-02-01 Impact factor: 6.261

Review 10. Going viral: a review of replication-selective oncolytic adenoviruses.

Authors: Christopher Larson; Bryan Oronsky; Jan Scicinski; Gary R Fanger; Meaghan Stirn; Arnold Oronsky; Tony R Reid
Journal: Oncotarget Date: 2015-08-21

15 in total

Review 1. Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements.

Authors: Su Shao; Xue Yang; You-Ni Zhang; Xue-Jun Wang; Ke Li; Ya-Long Zhao; Xiao-Zhou Mou; Pei-Yang Hu
Journal: Front Mol Biosci Date: 2022-02-28

Review 2. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Authors: Kenneth Lundstrom
Journal: Biologics Date: 2018-02-09

3. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.

Authors: A Galal El-Shemi; A Mohammed Ashshi; E Oh; B-K Jung; M Basalamah; A Alsaegh; C-O Yun
Journal: Gene Ther Date: 2017-09-19 Impact factor: 5.250

Review 4. The Double-Edged Sword Role of Viruses in Gastric Cancer.

Authors: Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Rafał Hrynkiewicz; Mikołaj Wołącewicz; Rafał Becht; Jacek Roliński
Journal: Cancers (Basel) Date: 2020-06-24 Impact factor: 6.639

5. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.

Authors: Dafei Chai; Dong Qiu; Zichun Zhang; Shang Yuchen Shi; Gang Wang; Lin Fang; Huizhong Li; Hailong Li; Hui Tian; Junnian Zheng
Journal: J Cell Mol Med Date: 2020-07-29 Impact factor: 5.310